This article provides insights on what the pharmaceutical and medical device industry can expect now that FDA Advisory Committee meetings are being held virtually in response to the COVID-19 pandemic.
Now that FDA has announced it will be conducting virtual Advisory Committee meetings as COVID-19 rages on, it’s clear pharmaceutical and medical device companies have many obstacles to overcome – including communications and technical challenges. Jim DiBiasi sat down with Kate Rawson from Pink Sheet to talk about what to expect, the challenges in running these high-stakes meetings virtually, and what 3D Communications is doing to prepare pharma clients for different scenarios.
Click here to read more: https://pink.pharmaintelligence.informa.com/PS142255/Virtual-US-FDA-Advisory-Committees-May-Have-One-Silver-Lining-Available-Experts
This article was originally featured in Pink Sheet on May 22, 2020.